Business Context and Reporting Period
This Form 8-K is a current report filed by Marker Therapeutics, Inc. on February 9, 2026. The filing addresses corporate governance matters regarding the scheduling of the company's 2026 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and contains no financial statements or performance metrics.
Material Changes
The primary material change disclosed is the advancement of the date for the 2026 Annual Meeting of Stockholders. The Board of Directors scheduled the meeting for May 1, 2026, which is more than 30 days prior to the anniversary of the 2025 Annual Meeting. Consequently, a new deadline for shareholder proposals has been established.
Guidance, Outlook, and Management Commentary
- Annual Meeting Date: May 1, 2026.
- Shareholder Proposal Deadline: Proposals intended for inclusion in the 2026 proxy statement under Rule 14a-8 must be received by March 9, 2026.
- Submission Address: Proposals must be delivered to the Corporate Secretary at 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021.
- Record Date and Location: These details will be specified in the upcoming proxy statement.
Key Facts for Investor Verification
- Verify the exact record date and meeting location once the proxy statement is released.
- Confirm the March 9, 2026 deadline for submitting shareholder proposals if intending to participate in the 2026 Annual Meeting.
- Note that the filing does not contain updates on clinical trial progress, pipeline status, or financial condition.